Respiratory viruses

Respiratory viruses encompass a diverse array of viral pathogens that primarily infect the human respiratory tract, including the nose, throat, and lungs (CDC, 2023). Major families include Orthomyxoviridae (Influenza), Coronaviridae (SARS-CoV-2, MERS-CoV), and Paramyxoviridae (Respiratory Syncytial Virus), each with distinct structural features and replication strategies (StatPearls, 2023). These viruses typically enter host cells via specific surface receptors, replicate their genetic material, and trigger inflammatory responses that can lead to symptoms ranging from mild cough to life-threatening pneumonia (NIH, 2024). While the term "respiratory viruses" refers to the pathogens themselves, therapeutic targets are usually specific viral proteins such as the influenza neuraminidase or the SARS-CoV-2 main protease (Nature Reviews Microbiology, 2021). Antiviral medications and vaccines are designed to recognize or inhibit these specific components to reduce viral spread and disease severity. Effective clinical management relies on rapid diagnostic testing and the timely administration of virus-specific or broad-spectrum antiviral agents (PubMed, 2022).

Other names

Respiratory viral pathogensRespiratory tract virusesViral respiratory infectionsRespiratory virus

Antiviral drugs targeting respiratory viruses operate through several distinct mechanisms: inhibition of viral attachment and entry into host cells, inhibition of viral uncoating, blockade of viral RNA or DNA polymerases to prevent genome replication, inhibition of viral proteases required for polyprotein processing, and inhibition of neuraminidase to prevent the release of viral progeny (Nature Reviews Microbiology, 2021; StatPearls, 2023).